Regulatory AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer BioSpaceDecnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer.HematologyRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioSpace Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: November date set for FDA decision on Sanofi’s Gaucher drugNext: GSK hails ‘unprecedented’ cure rates with hep B drug Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
